Literature DB >> 13587848

Studies of the plasmin system. III. Physical properties of the two plasmin inhibitors in plasma.

P S NORMAN, B M HILL.   

Abstract

There are two inhibitors of plasmin in the plasma proteins of the human. alpha1-antiplasmin is heat-labile and migrates as an alpha1-globulin on electrophoresis. It combines non-dissociably with plasmin at a rate that depends on temperature. alpha2-antiplasmin is relatively more heat-stable and migrates as an alpha2-globulin on electrophoresis. It combines dissociably with plasmin independently of temperature.

Entities:  

Keywords:  FIBRINOLYSIN/antagonists

Mesh：

Substances：

Year:  1958        PMID： 13587848      PMCID： PMC2136913          DOI： 10.1084/jem.108.5.639

Source DB:  PubMed          Journal:  J Exp Med        ISSN： 0022-1007            Impact factor:   14.307


  7 in total

1.  A proteolytic inhibitor with anticoagulant activity separated from human urine and plasma.

Authors:  N R SHULMAN
Journal:  J Biol Chem       Date:  1955-04       Impact factor: 5.157

2.  Quantitative aspects of antithrombin and heparin in plasma.

Authors:  D F WAUGH; M A FITZGERALD
Journal:  Am J Physiol       Date:  1956-03

3.  Zone electrophoresis in a starch supporting medium.

Authors:  H G KUNKEL; R J SLATER
Journal:  Proc Soc Exp Biol Med       Date:  1952-05

4.  Studies on the inhibition of proteolytic enzymes by serum. II. Demonstration that separate proteolytic inhibitors exist in serum; their distinctive properties and the specificity of their action.

Authors:  N R SHULMAN
Journal:  J Exp Med       Date:  1952-06       Impact factor: 14.307

5.  Studies of the plasmin system. II. Inhibition of plasmin by serum or plasma.

Authors:  P S NORMAN
Journal:  J Exp Med       Date:  1958-07-01       Impact factor: 14.307

6.  Studies of the plasmin system. I. Measurement of human and animal plasminogen; measurement of an activator in human serum.

Authors:  P S NORMAN
Journal:  J Exp Med       Date:  1957-09-01       Impact factor: 14.307

7.  Proteolytic enzymes; further studies on protein, polypeptide, and other inhibitors of serum proteinase, leucoproteinase, trypsin, and papain.

Authors:  D GROB
Journal:  J Gen Physiol       Date:  1949-11       Impact factor: 4.086
  7 in total
  16 in total

1.  In-vitro and in-vivo studies of a preparation of urokinase.

Authors:  G P MCNICOL; S B GALE; A S DOUGLAS
Journal:  Br Med J       Date:  1963-04-06

2.  Thrombolytic therapy.

Authors:  G P MCNICOL
Journal:  Proc R Soc Med       Date:  1963-05

3.  The lysis of artificially induced intravascular clots in man by intravenous infusions of streptokinase.

Authors:  A J JOHNSON; W R McCARTY
Journal:  J Clin Invest       Date:  1959-09       Impact factor: 14.808

4.  Total Hyphema with Special Reference to Treatment of the Experimental Lesion.

Authors:  S D Liebman
Journal:  Trans Am Ophthalmol Soc       Date:  1963

5.  Symposium on Fibrinolysis.

Authors:  J L Stafford
Journal:  Proc R Soc Med       Date:  1963-05

6.  Degradation of human fibrinogen by plasms alpha2-macroglobulin-enzyme complexes.

Authors:  P C Harpel; M W Mosesson
Journal:  J Clin Invest       Date:  1973-09       Impact factor: 14.808

7.  Serum protease inhibitors in the blood clearance of subtilisin A.

Authors:  M T Debanne; E Regoeczi; J Dolovich
Journal:  Br J Exp Pathol       Date:  1973-10

8.  The intestine as a source of plasminogen activator activity.

Authors:  H Gans; K Mori; R Quinlan; D Richter; B H Tan
Journal:  Ann Surg       Date:  1971-11       Impact factor: 12.969

9.  Immunoelectrophoretic analysis and radial immunodiffusion assay using plasminogen purified from fresh human plasma.

Authors:  E H Magoon; K F Austen; J Spragg
Journal:  Clin Exp Immunol       Date:  1974-06       Impact factor: 4.330

10.  FIBRINOLYTIC THERAPY OF THROMBOPHLEBITIS. TWENTY-FIVE CASES STUDIED WITH SERIAL VENOGRAMS.

Authors:  S P HECKER
Journal:  Calif Med       Date:  1964-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.